Table 2.
Soret (nm) | α (nm) | β (nm) | α:β | Difference: Peak (nm) | Difference: Trough (nm) | Absmax (1μM)# | Abs390 (1μM)% | KD (mM) | |
---|---|---|---|---|---|---|---|---|---|
CYP3A4* | 416 | 565 | 534 | 0.94 | --- | --- | --- | --- | --- |
1,2,3-TRZ | 422 | 565 | 538 | 0.77 | 430 | 394 | 0.058 | −0.023 | 14.3 +/− 0.5 |
1,2,4-TRZ | 422 | 569 | 537 | 0.74 | 432 | 395 | 0.0065 0.050 |
−0.025 | KD1=0.0390±0.0071 KD2 = 4.80 ± 0.22 |
IMZ | 424 | 570 | 538 | 0.73 | 432 | 407 | 0.065 | −0.027 | 0.381 +/− 0.011 |
CYP2C9* | 418 | 569 | 537 | 1.1 | --- | --- | --- | --- | --- |
1,2,3-TRZ | 420 | 570 | 540 | 0.84 | 433 | 411 | 0.041 | --- | 10.0 +/− 0.4 |
1,2,4-TRZ | 423 | 572 | 542 | 0.78 | 437 | 411 | 0.023 0.044 |
--- | KD1=0.198±0.040 KD2 = 2.85 ± 0.82 |
IMZ | 427 | 574 | 544 | 0.77 | 439 | 413 | 0.066 | --- | 0.0989 +/− 0.0018 |
20°C
Maximum peak trough intensity normalized to 1 μM
Used as an estimate of efficiency of type II ligand to decrease inherent high spin enzyme fraction (type IIa)(24).